Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis, 2025 by DelveInsight | Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology

DelveInsight's, Non-Small-Cell Lung cancer (NSCLC) - Pipeline Insight, 2025," report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that the Non-Small-Cell Lung Cancer (NSCLC) pipeline includes over 100 leading companies actively engaged in developing more than 120 treatment therapies.

Non-Small-Cell Lung cancer (NSCLC) Overview:

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, developing in the lung tissues. Unlike small cell lung cancer (SCLC), NSCLC generally grows more slowly, but it is often diagnosed at an advanced stage when it has already spread, making early detection and intervention essential. The distinction in naming comes from the microscopic appearance of the cells-SCLC cells are small and round, while NSCLC cells are larger. Although less aggressive than SCLC, NSCLC is still frequently detected late.

In the United States, lung cancer affects about 230,000 individuals each year and causes roughly 135,000 deaths annually. It remains the leading cause of cancer-related deaths in men and the second most common in women, claiming more lives than prostate, breast, brain, and colorectal cancers combined. Nonetheless, mortality rates have been declining thanks to public health measures targeting smoking and tobacco use.

The World Health Organization's 2015 classification of lung tumors, based on immunohistochemistry and light microscopy, helps guide treatment and prognosis. NSCLC is further categorized into subtypes, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Adenocarcinoma is the most common subtype, accounting for nearly half of all lung cancer cases. Squamous cell carcinoma, once the most prevalent, typically originates in the central airways (tracheobronchial tree), though it is increasingly identified in peripheral lung regions. Large cell carcinoma is less frequent and classified by exclusion, as it lacks distinctive features under immunohistochemical or electron microscopic analysis.

Risk factors for NSCLC can be modifiable or non-modifiable. Tobacco smoking remains the leading preventable cause. Other risks include alcohol consumption, secondhand smoke, environmental carcinogens (such as asbestos, radon, arsenic, chromium, and nickel), ionizing radiation, and polycyclic aromatic hydrocarbons.

Download our report @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

"Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Small-Cell Lung cancer (NSCLC) Therapeutics Market.

Key Takeaways from the Non-Small-Cell Lung cancer (NSCLC) Pipeline Report

DelveInsight's report on the Non-Small-Cell Lung Cancer (NSCLC) pipeline highlights a dynamic landscape, with over 100 companies actively advancing more than 120 therapies for NSCLC treatment.

In regulatory updates:

*
February 2024: The FDA granted traditional approval to tepotinib (Tepmetko) for adults with metastatic NSCLC harboring MET exon 14 skipping alterations.

*
August 2024: Approval was given for the combination of amivantamab and lazertinib in patients with advanced NSCLC with specific EGFR mutations, after clinical studies showed significant improvement in progression-free survival.

*
December 2024: The FDA issued accelerated approval for zenocutuzumab (Bizengri), the first treatment targeting NRG1 gene fusions in advanced, unresectable, or metastatic NSCLC.

*
December 2024: A subcutaneous injectable formulation of nivolumab and hyaluronidase (Opdivo Qvantig) received approval for previously cleared solid tumor indications, including NSCLC, offering a faster and more convenient alternative to intravenous infusion.

Key industry players such as Merck Sharp & Dohme LLC, Pfizer, Suzhou Puhe Pharmaceutical Technology, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio, Beijing Pearl Biotechnology, OncoResponse, Next Point Therapeutics, Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others are driving innovation to expand NSCLC treatment options.

Notable therapies under development include V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, and several additional candidates showing promise across different stages of clinical trials.

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis

The Non-Small-Cell Lung cancer (NSCLC) pipeline insights report 2025, provides insights into:

*
Provides comprehensive insights into key companies developing therapies in the Non-Small-Cell Lung cancer (NSCLC) Market.

*
Categorizes Non-Small-Cell Lung cancer (NSCLC) therapeutic companies by development stage: early, mid, and late-stage.

*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

*
Reviews emerging Non-Small-Cell Lung cancer (NSCLC) drugs under development based on:

*
Stage of development

*
Non-Small-Cell Lung cancer (NSCLC) Route of administration

*
Target receptor

*
Monotherapy vs. combination therapy

*
Non-Small-Cell Lung cancer (NSCLC) Mechanism of action

*
Molecular type

*
Offers detailed analysis of:

*
Company-to-company and company-academia collaborations

*
Non-Small-Cell Lung cancer (NSCLC) Licensing agreements

*
Funding and investment activities supporting future Non-Small-Cell Lung cancer (NSCLC) market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Non-Small-Cell Lung cancer (NSCLC) Emerging Drugs

*
V940: Merck Sharp & Dohme LLC

*
QL1706: Qilu Pharmaceutical Co., Ltd.

*
Zenocutuzumab (MCLA-128): Merus N.V.

*
ZW49: Zymeworks BC Inc.

Non-Small-Cell Lung cancer (NSCLC) Companies

Over 100 leading companies are actively engaged in developing therapies for Non-Small Cell Lung Cancer (NSCLC), with Merck Sharp & Dohme LLC advancing a drug candidate to the most progressed stage-Phase III clinical trials.

DelveInsight's report covers around 120+ products under different phases of Non-Small-Cell Lung cancer (NSCLC) clinical trials like

*
Non-Small-Cell Lung cancer (NSCLC) Late stage Therapies (Phase III)

*
Non-Small-Cell Lung cancer (NSCLC) Mid-stage Therapies (Phase II)

*
Non-Small-Cell Lung cancer (NSCLC) Early-stage Therapies (Phase I)

*
Non-Small-Cell Lung cancer (NSCLC) Pre-clinical and Non-Small-Cell Lung cancer (NSCLC) Discovery stage Therapies

*
Non-Small-Cell Lung cancer (NSCLC) Discontinued & Inactive Therapies

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the Non-Small-Cell Lung cancer (NSCLC) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Non-Small-Cell Lung cancer (NSCLC) Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Small-Cell Lung cancer (NSCLC) Therapies and Key Non-Small-Cell Lung cancer (NSCLC) Companies: Non-Small-Cell Lung cancer (NSCLC) Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Non-Small-Cell Lung cancer (NSCLC) Pipeline Therapeutic Assessment

- Non-Small-Cell Lung cancer (NSCLC) Assessment by Product Type

- Non-Small-Cell Lung cancer (NSCLC) By Stage

- Non-Small-Cell Lung cancer (NSCLC) Assessment by Route of Administration

- Non-Small-Cell Lung cancer (NSCLC) Assessment by Molecule Type

Download Non-Small-Cell Lung cancer (NSCLC) Sample report to know in detail about the Non-Small-Cell Lung cancer (NSCLC) treatment market @ Non-Small-Cell Lung cancer (NSCLC) Therapeutic Assessment [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Non-Small-Cell Lung cancer (NSCLC) Current Treatment Patterns

4. Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Non-Small-Cell Lung cancer (NSCLC) Late-Stage Products (Phase-III)

7. Non-Small-Cell Lung cancer (NSCLC) Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Small-Cell Lung cancer (NSCLC) Discontinued Products

13. Non-Small-Cell Lung cancer (NSCLC) Product Profiles

14. Non-Small-Cell Lung cancer (NSCLC) Key Companies

15. Non-Small-Cell Lung cancer (NSCLC) Key Products

16. Dormant and Discontinued Products

17. Non-Small-Cell Lung cancer (NSCLC) Unmet Needs

18. Non-Small-Cell Lung cancer (NSCLC) Future Perspectives

19. Non-Small-Cell Lung cancer (NSCLC) Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Small-Cell Lung cancer (NSCLC) Pipeline Reports Offerings [https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nonsmallcell-lung-cancer-nsclc-pipeline-analysis-2025-by-delveinsight-merck-sharp-dohme-llc-suzhou-puhe-pharmaceutical-technology-co-ltd-merus-nv-zymeworks-bc-inc-cytos-biotechnology]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.